Package Leaflet: Information for the User
tramadol, hydrochloride/dexketoprofen
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
If you have any further questions, ask your doctor or pharmacist.
Contents of the pack and other information
Enanplus contains the active substances tramadol hydrochloride and dexketoprofen.
Tramadol hydrochloride is a pain reliever belonging to the group of opioids that act on the central nervous system. It relieves pain by acting on specific nerve cells in the brain and spinal cord.
Dexketoprofen is a pain reliever belonging to the group of non-steroidal anti-inflammatory drugs (NSAIDs).
Enanplus is used for the symptomatic treatment of short-term moderate to severe acute pain in adults.
You should consult a doctor if you do not feel better or if you get worse.
Do not take Enanplus
Warnings and precautions
Consult your doctor before starting to take Enanplus:
Tramadol can cause physical and psychological dependence. When tramadol is taken for a prolonged period, its effect may decrease, and higher doses may be necessary (development of tolerance). In patients with a tendency to abuse medicines or those with drug dependence, treatment with Enanplus should only be carried out for short periods and under strict medical control.
Inform your doctor if any of these problems occur during treatment with Enanplus or if they have occurred in the past.
Talk to your doctor if you experience any of the following symptoms while taking Enanplus: extreme fatigue, loss of appetite, severe abdominal pain, nausea, vomiting, or low blood pressure. This may indicate that you have adrenal insufficiency (low cortisol levels). If you experience any of these symptoms, inform your doctor, who will decide whether you should take a hormonal supplement.
Tramadol is transformed in the liver by an enzyme. Some people have a variation of this enzyme, and this can affect each person differently. In some people, sufficient pain relief may not be achieved, while others are more likely to experience serious side effects. If you notice any of the following side effects, you should stop taking this medicine and consult a doctor immediately: slow or shallow breathing, confusion, drowsiness, constricted pupils, general malaise, or vomiting, constipation, loss of appetite.
There is a weak risk that you may experience a serotonin syndrome that can occur after taking tramadol in combination with certain antidepressants or tramadol monotherapy. Consult a doctor immediately if you experience any symptoms related to this serious syndrome (see section 4 "Possible side effects").
Respiratory disorders related to sleep
Enanplus may cause sleep-related respiratory disorders such as central sleep apnea (pauses in breathing during sleep) and sleep-related hypoxemia (low blood oxygen levels). These symptoms can be pauses in breathing during sleep, nocturnal awakenings due to difficulty breathing, difficulty maintaining sleep, or excessive daytime sleepiness. If you or someone else observes these symptoms, consult your doctor. Your doctor may consider reducing the dose.
Infections
Enanplus may mask the signs of an infection, such as pain. Consequently, Enanplus may delay appropriate treatment of the infection, which can increase the risk of complications. This has been observed in bacterial pneumonia and bacterial skin infections related to chickenpox. If you take this medicine while having an infection and the symptoms of the infection persist or worsen, consult a doctor without delay.
During chickenpox, it is recommended to avoid using this medicine.
Children and adolescents
This medicine has not been studied in children or adolescents. Therefore, safety and efficacy have not been established, and the medicine should not be used in children or adolescents.
Use in children with respiratory problems
The use of tramadol is not recommended in children with respiratory problems, as the symptoms of tramadol toxicity can worsen in these children.
Using Enanplus with other medicines
Inform your doctor if you are using, have recently used, or might use any other medicines, including those obtained without a prescription. There are some medicines that should not be taken together, and others that may require a dose adjustment if taken together.
Always inform your doctor if, in addition to Enanplus, you are taking any of the following medicines:
Combinations with Enanplus not recommended:
Combinations with Enanplus that require caution:
Combinations with Enanplus to be taken into account:
The analgesic effect of tramadol may be reduced, and the duration of action decreased if you also take medicines that contain:
The risk of side effects increases:
Taking Enanplus with alcohol
Do not drink alcohol during treatment with Enanplus, as it may increase the effect of the medicine.
For instructions on how to take Enanplus, see section 3.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine.
Dexketoprofen may cause kidney and heart problems in your fetus. It may affect your and your baby's tendency to bleed and delay or prolong labor more than expected. From the 20th week of pregnancy, dexketoprofen may cause kidney problems in your fetus, which can lead to low levels of amniotic fluid surrounding the baby (oligohydramnios) or constriction of a blood vessel (ductus arteriosus) in the baby's heart.
Tramadol is excreted in breast milk.
The use of Enanplus is contraindicated in pregnancy and during breastfeeding.
Driving and using machines
Enanplus may affect your ability to drive and use machines, as it can cause dizziness, blurred vision, or drowsiness as side effects of treatment. This occurs mainly when Enanplus is taken with medicines that affect mood and emotions or when taken with alcohol.
If you are affected, do not drive or use machines until the symptoms disappear.
This medicine contains less than 1 mmol of sodium (23 mg) per dose unit; i.e., it is essentially "sodium-free".
Follow exactly the administration instructions of this medication indicated by your doctor. In case of doubt, consult your doctor again.
The effective lowest dose should be used for the shortest time necessary to relieve symptoms. If you have an infection, consult a doctor without delay if symptoms (pain) persist or worsen (see section 2).
The dose of Enanplus you need may vary, depending on the type, intensity, and duration of the pain. Your doctor will indicate how many tablets you should take per day and for how long.
The recommended dose is generally 1 film-coated tablet (which corresponds to 75 mg of tramadol hydrochloride and 25 mg of dexketoprofen) every 8 hours, not exceeding 3 film-coated tablets per day (which corresponds to 225 mg of tramadol hydrochloride and 75 mg of dexketoprofen) and not exceeding 5 days of treatment.
Use in children and adolescents
Enanplus is not suitable for children and adolescents.
Elderly patients
If you are 75 years or older, your doctor may recommend prolonging the dosing interval, as your body may eliminate the medication more slowly.
Patients with severe liver or kidney disease/dialysis:
Patient with severe liver or kidney insufficiency should not take Enanplus.
In case of renal dysfunction, if in your case the insufficiency is mild, your doctor may recommend prolonging the dosing interval.
In case of liver dysfunction, if in your case the insufficiency is mild or moderate, your doctor may recommend prolonging the dosing interval.
Swallow the tablet with a sufficient amount of liquid (preferably with a glass of water).
Food delays the absorption of Enanplus, take the tablet at least 30 minutes before meals for faster action.
The score line is to help divide the tablet if you have difficulty swallowing it whole.
If you take more Enanplus than you should
If you have taken too much medication, inform your doctor immediately or go to the emergency department of your nearest hospital or call the Toxicology Information Service, phone: 91.562.04.20, indicating the medication and the amount taken. Please remember to always carry the medication package or this leaflet with you.
The symptoms of overdose of this medication are:
If you forget to take Enanplus
Do not take a double dose to make up for forgotten doses. Take the next dose when scheduled (according to section 3 "How to take Enanplus").
If you stop treatment with Enanplus
Generally, no after-effects are expected after stopping treatment with Enanplus.
However, in rare cases, patients who have been taking Enanplus tablets for some time may feel unwell if they stop taking it suddenly. They may feel agitation, anxiety, nervousness, or tremors, confusion, hyperactivity, have difficulty sleeping, and gastrointestinal or stomach disorders. Rarely, people may suffer from panic attacks, hallucinations, delirium, paranoia, or feel a loss of identity. They may experience unusual perceptions such as itching, tingling, and numbness, ringing in the ears (tinnitus). Very rarely, other unusual symptoms such as confusion, delirium, feeling of being detached from oneself (depersonalization), change in perception of reality (derealization), illusions of persecution (paranoia) have been observed. Please consult your doctor if you experience any of these effects after stopping Enanplus.
If you have any other questions about the use of this medication, ask your doctor.
Like all medications, this medication can cause side effects, although not everyone will experience them.
Possible side effects are detailed below according to their likelihood of occurrence.
You should see a doctor immediately if you experience symptoms of an allergic reaction such as swelling of the face, tongue, and/or throat, and/or difficulty swallowing or urticaria along with difficulty breathing.
Stop using Enanplus if you experience a skin rash, any lesion inside the mouth or on the mucous membranes, or any sign of allergy.
Very common side effects (may affect more than 1 in 10 people):
Common side effects (may affect up to 1 in 10 people):
Uncommon side effects (may affect up to 1 in 100 people):
Rare side effects (may affect up to 1 in 1,000 people):
Psychological side effects may occur during treatment with Enanplus. The intensity and nature of these may change (depending on the patient's personality and treatment duration):
Cases of worsening asthma have been reported.
Withdrawal symptoms may occur when treatment is stopped suddenly (see "If you stop treatment with Enanplus").
Cases of seizures have been reported, mainly when high doses of tramadol are administered or when tramadol is taken with other medications that may cause them.
Very rare (may affect up to 1 in 10,000 people):
Unknown frequency (cannot be estimated from available data)
Inform your doctor immediately if you notice any gastrointestinal side effects at the start of treatment (e.g., stomach pain or burning, or bleeding), if you have previously experienced any of these side effects due to prolonged treatment with anti-inflammatory medications, and especially if you are an elderly patient.
The most common side effects during treatment with Enanplus are nausea and dizziness, which affect more than 1 in 10 patients.
During treatment with NSAIDs, cases of fluid retention and swelling (especially in ankles and legs), increased blood pressure, and heart failure have been reported.
Medications like Enanplus may be associated with a small increased risk of suffering a heart attack or stroke.
In patients with immune system disorders that affect connective tissue (systemic lupus erythematosus or mixed connective tissue disease), anti-inflammatory medications may rarely cause fever, headache, and neck stiffness.
Reporting side effects
If you experience any side effects, consult your doctor, pharmacist, or nurse, even if it is a possible side effect not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of sight and reach of children.
Do not use this medication after the expiration date shown on the packaging and on the blister pack after EXP. The expiration date is the last day of the month indicated.
This medication does not require any special storage temperature.
Keep in the original package to protect from light.
Medications should not be disposed of through wastewater or household waste. Deposit the packaging and any unused medication in the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and any unused medication. This will help protect the environment.
Composition of Enanplus:
Tablet core: Microcrystalline cellulose; Pregelatinized corn starch; Sodium croscarmellose; Sodium stearyl fumarate; Anhydrous colloidal silica.
Coating:Opadry II white 85F18422 composed of polyvinyl alcohol; Titanium dioxide; Macrogol/PEG 3350; Talc.
Appearance of the product and package contents:
Almost white or slightly yellowish, oval, film-coated tablets with a score line on one side and an "M" engraved on the other side, in plastic/aluminum blisters with manual pressure extraction.
Enanplus is available in packages of 2, 4, 10, 15, 20, 30, 50, or 100 film-coated tablets and in multi-packages consisting of 5 packages, each containing 100 film-coated tablets.
Not all package sizes may be marketed.
Marketing authorization holder and manufacturer:
Marketing authorization holder
LABORATORIOS MENARINI, S.A.
Alfons XII, 587 - Badalona (Barcelona)
Spain
Manufacturer
Menarini – Von Heyden GmbH
Leipziger Strasse 7-13
01097 Dresden
Germany
This medication is authorized in the Member States of the European Economic Area under the following names:
Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Finland, Greece, Hungary, Ireland, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Sweden, United Kingdom (Northern Ireland): Skudexa
France: Skudexum
Italy: Lenizak
Spain: Enanplus
Date of the last revision of this leaflet: December 2022
Detailed information about this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/